These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 16944348)

  • 41. Patterns of disease activity in multiple sclerosis.
    Truyen L; Gheuens J; Martin JJ
    BMJ; 1990 May; 300(6734):1272. PubMed ID: 2354301
    [No Abstract]   [Full Text] [Related]  

  • 42. Measuring evoked responses in multiple sclerosis.
    Comi G; Leocani L; Medaglini S; Locatelli T; Martinelli V; Santuccio G; Rossi P
    Mult Scler; 1999 Aug; 5(4):263-7. PubMed ID: 10467386
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sodium accumulation is associated with disability and a progressive course in multiple sclerosis.
    Paling D; Solanky BS; Riemer F; Tozer DJ; Wheeler-Kingshott CA; Kapoor R; Golay X; Miller DH
    Brain; 2013 Jul; 136(Pt 7):2305-17. PubMed ID: 23801742
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Magnetization transfer can predict clinical evolution in patients with multiple sclerosis.
    Santos AC; Narayanan S; de Stefano N; Tartaglia MC; Francis SJ; Arnaoutelis R; Caramanos Z; Antel JP; Pike GB; Arnold DL
    J Neurol; 2002 Jun; 249(6):662-8. PubMed ID: 12111296
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multiple sclerosis: it's not the disease you thought it was.
    Rolak LA
    Clin Med Res; 2003 Jan; 1(1):57-60. PubMed ID: 15931287
    [No Abstract]   [Full Text] [Related]  

  • 46. Tumefactive lesion in multiple sclerosis.
    Findling O; Sellner J; Ozdoba C; Arnold M
    Acta Neurol Belg; 2007 Dec; 107(4):134. PubMed ID: 18416290
    [No Abstract]   [Full Text] [Related]  

  • 47. Differential diagnosis between acute disseminated encephalomyelitis and multiple sclerosis during the first episode.
    Tavazzi E; Ravaglia S; Franciotta D; Marchioni E
    Arch Neurol; 2008 May; 65(5):676-7; author reply 677. PubMed ID: 18474751
    [No Abstract]   [Full Text] [Related]  

  • 48. Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis.
    Portaccio E; Stromillo ML; Goretti B; Zipoli V; Siracusa G; Battaglini M; Giorgio A; Bartolozzi ML; Guidi L; Sorbi S; Federico A; Amato MP; De Stefano N
    Neurology; 2009 Aug; 73(7):498-503. PubMed ID: 19641173
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A dynamic view of the blood-brain barrier in active multiple sclerosis lesions.
    Lassmann H
    Ann Neurol; 2011 Jul; 70(1):1-2. PubMed ID: 21710628
    [No Abstract]   [Full Text] [Related]  

  • 50. [Laboratory diagnosis of multiple sclerosis].
    Sand T; Stovner LJ; Rinck PA; Nilsen G; Romslo I
    Tidsskr Nor Laegeforen; 1991 Aug; 111(18):2267-70. PubMed ID: 1896982
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis.
    Arnold DL; Riess GT; Matthews PM; Francis GS; Collins DL; Wolfson C; Antel JP
    Ann Neurol; 1994 Jul; 36(1):76-82. PubMed ID: 8024266
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Unsuspected multiple sclerosis in patients with psychiatric disorders: a magnetic resonance imaging study.
    Lyoo IK; Seol HY; Byun HS; Renshaw PF
    J Neuropsychiatry Clin Neurosci; 1996; 8(1):54-9. PubMed ID: 8845702
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Brain damage as detected by magnetization transfer imaging is less pronounced in benign than in early relapsing multiple sclerosis.
    De Stefano N; Battaglini M; Stromillo ML; Zipoli V; Bartolozzi ML; Guidi L; Siracusa G; Portaccio E; Giorgio A; Sorbi S; Federico A; Amato MP
    Brain; 2006 Aug; 129(Pt 8):2008-16. PubMed ID: 16815879
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MRI evaluation of grey matter atrophy and disease course in multiple sclerosis: an overview of current knowledge.
    Jacobsen CO; Farbu E
    Acta Neurol Scand Suppl; 2014; (198):32-6. PubMed ID: 24588504
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An fMRI study of planning-related brain activity in patients with moderately advanced multiple sclerosis.
    Lazeron RH; Rombouts SA; Scheltens P; Polman CH; Barkhof F
    Mult Scler; 2004 Oct; 10(5):549-55. PubMed ID: 15471372
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Brain atrophy measurements should be used to guide therapy monitoring in MS - NO.
    Barkhof F
    Mult Scler; 2016 Oct; 22(12):1524-1526. PubMed ID: 27335096
    [No Abstract]   [Full Text] [Related]  

  • 57. Measuring brain atrophy in multiple sclerosis.
    De Stefano N; Battaglini M; Smith SM
    J Neuroimaging; 2007 Apr; 17 Suppl 1():10S-15S. PubMed ID: 17425728
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A longitudinal fMRI study on motor activity in patients with multiple sclerosis.
    Pantano P; Mainero C; Lenzi D; Caramia F; Iannetti GD; Piattella MC; Pestalozza I; Di Legge S; Bozzao L; Pozzilli C
    Brain; 2005 Sep; 128(Pt 9):2146-53. PubMed ID: 15901646
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Brain atrophy measurements should be used to guide therapy monitoring in MS - YES.
    Zivadinov R; Dwyer MG; Bergsland N
    Mult Scler; 2016 Oct; 22(12):1522-1524. PubMed ID: 27335098
    [No Abstract]   [Full Text] [Related]  

  • 60. MR brain iron mapping in MS: a potential neurodegenerative marker or just another technique?
    Rovira A; Montalban X
    Neurology; 2011 Nov; 77(18):1660-1. PubMed ID: 21975201
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.